News Posts List
Obesity fuelling rise in kidney cancer cases
04/25/2017
Being obese, with a body mass index ( BMI) of 30 or more, increases the risk of getting kidney cancer. It causes around 25% of cases in men and 22% in women.
Argos Reports Interim Results of the ADAPT Trial
04/20/2017
A total of 462 patients were enrolled in the ADAPT study and randomized 2:1 between combination treatment with Rocapuldencel-T and sunitinib (combination arm) vs. sunitinib monotherapy (control arm).
Hundreds of Experts Attend European International Kidney Cancer Symposium
04/20/2017
Kidney Cancer Association (KCA) sponsors 12th annual medical meeting in Munich, Germany
Adjuvant Treatment for High-Risk Clear Cell Renal Cancer
03/13/2017
Do high-risk clear cell renal cancer (ccRCC) (≥pT3 or node-positive) patients receiving adjuvant sunitinib or sorafenib have improved disease-free survival, and does the dose intensity of either drug affect outcome?
"Richness of Choices" Available in Kidney Cancer, But Patient Selection Is Key
03/11/2017
Between the frontline and second-line settings, there are multiple treatment options available for patients with renal cell carcinoma (RCC), but it is critically important for oncologists to decide on an agent with a patient’s characteristics—and goals—in mind, according to Eric Jonasch, MD.
Michigan Gov. Rick Snyder Proclaims March: Kidney Health and Cancer Awareness Month
03/09/2017
The precise cause of kidney cancer is unknown, however the two main causes of kidney failure are diabetes and high blood pressure, which are responsible for more than 70 percent of all kidney failure cases. Therefore, kidney failure and disease can often be delayed or prevented...
Gene Expresion Analysis of A-498 cells after treatment with Englerin A
02/25/2017
Natural products possess enormous structural and chemical diversity and are a rich source of drugs or drug-like leads. Although the final products may not necessarily represent the active ingredients of the natural source, the majority of all drugs in the market have their origin in nature. Englerin A is guaiane sesquiterpene that was isolated from the Tanzanian plant Phyllanthus engleri and has attracted much attention because of its unique structure and cytotoxicity profile in cancer cells.
Your participation in this research project can help ensure that the company’s brochure and other materials are relevant to patients
02/24/2017
In appreciation of your time and valuable contribution, you will receive an honorarium of $150 payable upon successful completion of the telephone interview.
Argos says independent committee predicts trial failure
02/24/2017
Argos Therapeutics Inc said on Wednesday that an independent data monitoring committee concluded that the company's experimental treatment for metastatic renal cell carcinoma would likely fail.
Tumor Ablation Market is Driven by Rise in Cancer Incidence
02/23/2017
Tumor ablation is a treatment that destroys cancerous tumors without removing them. This is done using a probe that utilizes thermal energy to heat or cool tumorigenic tissue to cytotoxic levels. Techniques such as computed tomography (CT), ultrasound (US), and magnetic resonance imaging (MRI) are used to guide and position the needle probe into the tumor. Tumor ablative techniques are used in patients having few tumors which are small in size.
News Feed